IGNAZ trial interim results highlight HI-Bio’s potential to differentiate in IgAN space: GlobalData
According to the results, the use of MOR-202 (felzartamab) demonstrated a deep and durable reduction in proteinuria in patients…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.